A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Clinical trial NCT04907539 · COMPLETED
Trial details
- NCT number
- NCT04907539
- Sponsor
- Redx Pharma Ltd
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-08
- Primary completion
- 2024-04-02
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.